Dr. Ari Baron, MD
Claim this profileAlta Bates Summit Medical Center-Herrick Campus
Expert in Cancer
Studies Lung Cancer
29 reported clinical trials
67 drugs studied
Area of expertise
1Cancer
Global LeaderStage IV
Stage III
BRAF negative
2Lung Cancer
Stage IV
Stage III
RET positive
Affiliated Hospitals
Clinical Trials Ari Baron, MD is currently running
Combination Therapy
for Multiple Myeloma
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and dexamethasone may be more effective in shrinking the cancer or preventing it from returning, compared to continuing on daratumumab, lenalidomide, and dexamethasone.
Recruiting2 awards Phase 332 criteria
Pembrolizumab + Olaparib
for Pancreatic Cancer
This phase II trial studies whether adding pembrolizumab to olaparib (standard of care) works better than olaparib alone in treating patients with pancreatic cancer with germline BRCA1 or BRCA2 mutations that has spread to other places in the body (metastatic). BRCA1 and BRCA2 are human genes that produce tumor suppressor proteins. These proteins help repair damaged deoxyribonucleic acid (DNA) and, therefore, play a role in ensuring the stability of each cell's genetic material. When either of these genes is mutated, or altered, such that its protein product is not made or does not function correctly, DNA damage may not be repaired properly. As a result, cells are more likely to develop additional genetic alterations that can lead to some types of cancer, including pancreatic cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Olaparib is an inhibitor of PARP, a protein that helps repair damaged DNA. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. The addition of pembrolizumab to the usual treatment of olaparib may help to shrink tumors in patients with metastatic pancreatic cancer with BRCA1 or BRCA2 mutations.
Recruiting1 award Phase 237 criteria
More about Ari Baron, MD
Clinical Trial Related7 years of experience running clinical trials · Led 29 trials as a Principal Investigator · 14 Active Clinical TrialsTreatments Ari Baron, MD has experience with
- Pembrolizumab
- Nivolumab
- Irinotecan Hydrochloride
- Fluorouracil
- Leucovorin Calcium
- Ramucirumab
Breakdown of trials Ari Baron, MD has run
Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Colorectal Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Ari Baron, MD specialize in?
Ari Baron, MD focuses on Cancer and Lung Cancer. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is Ari Baron, MD currently recruiting for clinical trials?
Yes, Ari Baron, MD is currently recruiting for 14 clinical trials in Berkeley California. If you're interested in participating, you should apply.
Are there any treatments that Ari Baron, MD has studied deeply?
Yes, Ari Baron, MD has studied treatments such as Pembrolizumab, Nivolumab, Irinotecan Hydrochloride.
What is the best way to schedule an appointment with Ari Baron, MD?
Apply for one of the trials that Ari Baron, MD is conducting.
What is the office address of Ari Baron, MD?
The office of Ari Baron, MD is located at: Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California 94704 United States. This is the address for their practice at the Alta Bates Summit Medical Center-Herrick Campus.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.